By Anthony O. Goriainoff

 

AstraZeneca PLC said Tuesday that its Lynparza drug's supplemental new drug application has been accepted and granted Priority Review by the U.S. Food and Drug Administration.

Lynparza is used for the treatment of patients with early breast cancer who have already been treated with chemotherapy either before or after surgery, the London-listed company said.

The Anglo-Swedish pharmaceutical company said the application was based on results from the OlympiA phase 3 trial which showed Lynparza demonstrated a statistically significant improvement in invasive disease-free survival.

 

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

 

(END) Dow Jones Newswires

November 30, 2021 02:34 ET (07:34 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Dez 2021 até Jan 2022 Click aqui para mais gráficos Astrazeneca.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Jan 2021 até Jan 2022 Click aqui para mais gráficos Astrazeneca.